Saturday 17 October 2026
Export TELA’s income statement to Excel — free account
TELA Bio, Inc.
TELA Healthcare Medical Devices
TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 4.49%, EPS grew 9.09%, free cash flow fell 17.7% and total debt rose 35.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
0.98
0.03
−2.97%
Follow TELA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.54 | 0.44 | 0.69 | 0.88 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.59) | (3.18) | (11.38) | (11.83) | |
P/B ratio |
0.00 | 0.00 | 8.78 | 43.47 | |
Price to Tangible BV |
0.00 | 0.00 | 11.18 | 657.08 | |
EV/Sales |
0.90 | 0.68 | 0.79 | 1.07 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.31) | (1.86) | (2.25) | (2.68) | |
EV/FCF |
(2.08) | (1.66) | (2.01) | (2.40) | |
Quick Ratio |
2.20 | 2.76 | 3.40 | 2.41 | |
Current Ratio |
2.99 | 3.61 | 4.20 | 3.30 | |
Net Debt/EBITDA |
(2.85) | (1.59) | (0.75) | (1.61) | |
Debt/Assets |
93.88% | 79.93% | 68.35% | 67.37% | |
Debt/Equity |
(3.53) | (10.74) | 8.82 | 26.65 | |
Asset Turnover |
1.26 | 1.10 | 0.96 | 1.34 | |
Operating CF/Net income |
0.83 | 0.91 | 0.54 | 0.66 | |
Capex/Depreciation |
(0.22) | (0.45) | (0.40) | (0.85) | |
Interest Coverage |
(4.47) | (5.13) | (4.06) | (6.29) | |
Research and Development Expense of Revenue |
14.12% | 12.29% | 10.20% | 11.35% | |
Selling, General and Administrative Expense of Revenue |
106.28% | 108.63% | 87.57% | 92.68% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
3.18% | 4.28% | 3.89% | 4.62% | |
Graham Net Nets |
(0.49) | (0.30) | 0.01 | (0.06) | |
Graham Number |
2.19 | 1.27 | 0.00 | 0.00 | |
Earnings Yield |
(102.67%) | (127.42%) | (70.34%) | (59.73%) | |
Free Cash Flow Yield |
(80.40%) | (93.52%) | (57.16%) | (50.98%) | |
Revenue per Share |
0.34 | 0.33 | 0.44 | 0.46 | |
Operating CF per Share |
(0.16) | (0.20) | (0.10) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | (0.20) | (0.11) | (0.13) | |
Cash per Share |
0.53 | 0.69 | 1.08 | 0.65 | |
Shareholders Equity per Share |
(0.28) | (0.09) | 0.13 | 0.03 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.28) | (0.09) | 0.13 | 0.03 | |
Free Cash Flow |
(9.44) | (11.29) | (4.96) | (5.93) | |
Working Capital |
36.27 | 46.47 | 57.61 | 39.07 | |
Capital Expenditures |
(0.06) | (0.12) | (0.09) | (0.21) | |
Net Current Asset Value |
(21.11) | (10.79) | 0.48 | (3.98) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.44 | 10.14 | 10.22 | 11.25 | |
Average Payables |
2.31 | 3.95 | 2.23 | 2.43 | |
Average Inventory |
11.22 | 12.87 | 11.90 | 12.58 | |
Average Assets |
63.64 | 73.57 | 83.99 | 57.30 | |
Average Common Equity |
(3.34) | 6.46 | 17.39 | (2.36) |
Columns are period end dates